Delcath launches pivotal study of Melphalan/HDS in type of liver caner

|About: Delcath Systems, Inc. (DCTH)|By:, SA News Editor

Delcath Systems (DCTH) initiates its registrational study of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with intrahepatic cholangiocarcinoma (ICC), the second most common form of liver cancer.

The primary endpoint of the 295-subject study is overall survival.

Subscribe for full text news in your inbox